Pelvital USA, Inc., an Eagan, MN-based women’s health company, closed an additional $2.32M in its seed-plus funding round.
The round was led by Boomerang Ventures, with participation from Pier 70 Ventures, Life Science Angels, Tech Coast Angels Orange County, and Blue Pacific Fund. Concurrent with the close, Preetha Ram, PhD, Managing Partner at Pier 70 Ventures, joined the Pelvital Board of Directors.
The seed plus funding will be instrumental in expediting the commercialization of Flyte, Pelvital’s novel FDA-cleared treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles.
Led by Lydia Zeller, President and CEO, Pelvital USA, Inc. is a women’s health medical device company empowering women and clinicians to restore pelvic health with effective, convenient products backed by strong clinical evidence. Their first product, Flyte®, is an FDA-cleared novel in-home treatment for stress urinary incontinence and weakened pelvic floor muscles. Flyte delivers the therapeutic treatment modality of mechanotherapy to the pelvic floor.
Flyte is effective for mild, moderate, and severe SUI. Typical treatment is only five minutes per day for six weeks.
FinSMEs
22/04/2024